Caprock Group LLC Takes $304,000 Position in argenx SE (NASDAQ:ARGX)

Caprock Group LLC purchased a new position in shares of argenx SE (NASDAQ:ARGX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 494 shares of the company’s stock, valued at approximately $304,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ARGX. FMR LLC raised its stake in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Janus Henderson Group PLC grew its holdings in argenx by 0.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after purchasing an additional 10,975 shares in the last quarter. Wellington Management Group LLP increased its stake in argenx by 13.0% during the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after buying an additional 55,617 shares during the period. Alkeon Capital Management LLC lifted its holdings in argenx by 15.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock worth $187,018,000 after buying an additional 45,000 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in argenx by 0.6% in the 3rd quarter. Jennison Associates LLC now owns 237,966 shares of the company’s stock valued at $128,997,000 after buying an additional 1,528 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of NASDAQ ARGX opened at $657.97 on Friday. The firm has a market capitalization of $39.98 billion, a PE ratio of -747.69 and a beta of 0.58. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21. The business’s fifty day moving average price is $636.51 and its two-hundred day moving average price is $574.93.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. JPMorgan Chase & Co. increased their target price on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $717.00 price target (up previously from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Wedbush reiterated an “outperform” rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.